Granulocytosis refers to an abnormal increase in the number of circulating granulocytes, to be distinguished from agranulocytosis (collapse of neutrophils), which occupies the majority of research results. Here, we focus on both aspects of this granulocyte imbalance, with particular attention to mechanisms often overlooked by mainstream articles.
Neutrophil thresholds and clinical significance of granulocytosis
Granulocytosis is defined by an absolute number of granulocytes (neutrophils, eosinophils, or basophils) exceeding reference values on the blood count. In practice, it is neutrophilic granulocytosis that draws attention, as it represents the majority of cases.
See also : Everything You Need to Know About the PTT Pension Fund: Operation, Rights, and Procedures
The increase in neutrophils is not a diagnosis in itself. It points towards a reactive process (bacterial infection, inflammation, tissue necrosis, corticosteroid therapy) or, more rarely, a myeloproliferative disorder. The distinction relies on the kinetics of appearance, clinical context, and blood smear analysis.
As stated in the definition of granulocytosis on the Pharmanco website, this biological anomaly must always be interpreted in light of the complete white blood cell count and the patient’s clinical picture.
Further reading : Everything You Need to Know About Permitted Colors for Buildings in France: Standards and Tips
In contrast, agranulocytosis corresponds to a neutrophil count below 0.5 G/L, exposing the patient to a major infectious risk requiring urgent management. This critical threshold justifies immediate hospitalization in most protocols.
Drug-induced agranulocytosis: clozapine and new pharmacovigilance signals
Isolated acute agranulocytoses are most often drug-induced. Synthetic antithyroid drugs, certain antibiotics, and antipsychotics are among the classes most frequently implicated.
The case of clozapine deserves particular attention. This atypical antipsychotic, used in treatment-resistant schizophrenia, has a narrow therapeutic margin. Pharmacovigilance reports highlight a risk of agranulocytosis that necessitates close hematological monitoring, as outlined in updated product characteristic summaries (RCP).
Since 2020, several European countries have strengthened their national monitoring programs for clozapine. These measures impose strict neutrophil thresholds to initiate or continue treatment, with immediate cessation if the count falls below the defined threshold. Late cases of agranulocytosis, occurring after several years of continuous treatment, have motivated these enhancements.
Immunological and toxic mechanisms
Two main mechanisms explain drug-induced agranulocytosis. The immuno-allergic mechanism involves the formation of antibodies directed against neutrophils or their bone marrow precursors. The dose-dependent toxic mechanism causes direct destruction of granulocyte lineage cells in the bone marrow.
The differential diagnosis between these two mechanisms determines the course of action. An immuno-allergic mechanism contraindicates any reintroduction of the implicated drug, while a toxic mechanism may sometimes allow for a resumption at a reduced dose under supervision.
Alert symptoms and biological diagnosis of agranulocytosis
In more than 90% of cases according to university data, drug-induced agranulocytosis presents as a severe infectious picture with sudden onset: high fever with chills, sometimes accompanied by ulceronecrotic lesions in the mouth and throat.
Other common infectious entry points are ENT, skin, pulmonary, and digestive. The absence of neutrophils eliminates the usual inflammatory response, which can make local signs of infection misleading or absent.
- The blood count with white blood cell differential confirms the diagnosis by showing an isolated collapse of neutrophils, with other lineages usually preserved in pure drug-induced forms.
- The bone marrow biopsy clarifies the mechanism (maturation blockage or disappearance of granular precursors) and helps rule out an underlying hematological disorder.
- The chronological etiological investigation remains the key piece: identification of all medications introduced in the preceding weeks, with particular attention to recognized risk molecules.
Treatment of agranulocytosis and hospital management
Acute agranulocytosis requires emergency hospitalization. Immediate cessation of any suspected medication is the first measure, without waiting for additional results.
Management relies on three simultaneous axes:
- Broad-spectrum antibiotic therapy initiated as soon as microbiological samples are taken, without waiting for blood culture results. Any delay increases mortality.
- Protective isolation to limit exposure to nosocomial pathogens, with enhanced aseptic measures.
- Administration of granulocyte growth factors (G-CSF) to accelerate the reconstitution of the neutrophil lineage, when the depth and expected duration of agranulocytosis justify it.
Prognosis and follow-up after agranulocytosis
Bone marrow recovery usually occurs within one to three weeks after cessation of the responsible medication, provided that the diagnosis was made quickly. The prognosis primarily depends on the timeliness of management and the severity of the initial infection.
The identified responsible medication must be definitively contraindicated for the patient, with notification in the medical record and reporting to the pharmacovigilance center. For clozapine, national monitoring registers allow for centralized follow-up of patients who have experienced this incident.
Granulocytosis and its counterpart, agranulocytosis, illustrate the importance of the blood count as a first-line screening tool. The recent strengthening of monitoring programs for risk molecules, particularly clozapine, reflects an increased awareness of late accidents. Any unexplained fever in a patient on risk treatment warrants immediate white blood cell count monitoring.